Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Structural Basis for Therapeutic Intervention of uPA/uPAR System

Author(s): Jacky Chi Ki Ngo, Longguang Jiang, Zhonghui Lin, Cai Yuan, Zhuo Chen, Xu Zhang, Haiyang Yu, Jundong Wang, Lin Lin and Mingdong Huang

Volume 12, Issue 12, 2011

Page: [1729 - 1743] Pages: 15

DOI: 10.2174/138945011797635911

Price: $65

Abstract

Urokinase-type plasminogen activator (uPA) is one of the two physiological serine proteases responsible for the activation of plasminongen to plasmin. uPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins. In addition to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration. It is beyond reasonable doubt that this enzyme system plays a central role in tumor biology and represents a high potential target for therapeutic intervention of tumor growth and metastasis. During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors. Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, especially a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors. Recent progress on uPA inhibitors will be summarized in this article. The unique structural features and the druggable potentials of these new structures will also be discussed.

Keywords: uPA, uPAR, SMB crystal structures, inhibitors, crystal structures, inhibitors, serine proteases, plasminogen activation, antagonist, tumor, signaling


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy